← Back to Companies
PARTICLEMEHCQAnalysis: 2026-01-27

23Andme

GPI SCORE
7.85
Market Cap: $23.64M
THE PATTERN

The Data Asset Trap

23andMe exemplifies the Data Asset Trap: when your most valuable asset becomes your heaviest liability. The company owns 15 million genetic profiles, one of the largest human genetic databases in the world. This asset was supposed to unlock recurring revenue through therapeutics, data partnerships, and personalized health services. Instead, it became a structural anchor. The database requires perpetual compliance costs (HIPAA, GDPR, state privacy laws). It attracts litigation (data breach settlements up to $86.5 million). It cannot be sold without customer consent, which is eroding rapidly (1.9 million deletion requests post-bankruptcy). The core business model is fundamentally broken: one-time genetic testing with no recurring revenue. Customers pay $99-$199 once, get their ancestry and h

DIMENSION SCORES
KEY NUMBERS
Market cap: $23.64M (January 2026), down 99.6% from $6B peak (June 2021)
Revenue: $208.78M TTM (December 2024), declining from $299M in 2022
Employees: 582 (post-layoffs), down from 1,000+ at peak, 40% reduction November 2024
Customers: 15 million genetic profiles in database
Data deletion requests: 1.9 million (15% of customer base) post-bankruptcy
Data breach: 6.9 million customers exposed (October 2023)
ICO fine: £2.31M for inadequate data security
Data breach settlements: Up to $86.5M in class actions
TRANSFORMATION SIGNALS
ENABLERS
  • +15 million customer genetic database remains a valuable asset for research and drug development partnerships
  • +TTAM Research Institute acquisition removes public market pressure, allows long-term restructuring without quarterly earnings
  • +Downsizing from 155K to 30K sq ft reduces fixed costs by 80%, right-sizes footprint for current revenue
  • +Shuttering therapeutics division eliminates capital-intensive R&D with no ROI, focuses resources on core testing business
  • +AI/ML firms (OpenAI, Google) interested in genetic data for training datasets, potential partnership revenue stream
  • +Consumer genomics market still growing globally, competitors like AncestryDNA and MyHeritage remain viable proving business model works
FRICTION
  • −One-and-done business model with no recurring revenue, customers buy test once and never return (structural economics broken)
  • −Data breach exposed 6.9 million customers, £2.31M ICO fine, ongoing class action settlements up to $86.5M (trust destroyed)
  • −1.9 million customers (15% of base) requested data deletion post-bankruptcy, eroding the core asset in real-time
  • −Privacy regulations and 27-state coalition lawsuit restrict data monetization without explicit consent (legal lock-in)
  • −Talent exodus
  • −Anne Wojcicki circular leadership (resigned as CEO, bought company via TTAM) signals founder dependency, not systemic health
"The database is both the company's greatest asset and its heaviest anchor. At GPI 7.85, you cannot sell it, you cannot leverage it, and you cannot ignore it."

WANT YOUR COMPANY ANALYZED?

Get a full GPI breakdown across all 7 dimensions.

START WITH THE DIAGNOSTIC